Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)

NCT02268383 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
75
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA